Wayne Winegarden
Contributor|Policy

ABOUT
I am a Senior Fellow in Business and Economics at the Pacific Research Institute and the Director of PRI's Center for Medical Economics and Innovation. My research explores the connection between macroeconomic policies and economic outcomes, with a focus...
I am a Senior Fellow in Business and Economics at the Pacific Research Institute and the Director of PRI's Center for Medical Economics and Innovation. My research explores the connection between macroeconomic policies and economic outcomes, with a focus on the health care and energy industries. I have over 25 years of experience advising Fortune 500 companies, medium and small businesses, and trade associations. I received my Ph.D. in economics from George Mason University.
Read MoreRead Less
LATESTARCHIVE
836 views  |  
Nov 7, 2019

There Are High Costs From Implementing Drug Price Controls

As part of the chorus calling for drug price controls, the New York Times editorial page claims that Americans need to accept slightly fewer new drugs in exchange for better prices on the medications that already exist. This supposition is false and dangerous to patients' health.
1,064 views  |  
Oct 29, 2019

We Need A Cure For The Arrogance Of Drug Price Control Advocates

Price controls generate savings by denying effective treatments to patients who currently lack one. A better approach implements reforms that promote the use of biosimilars and increase price transparency. These reforms create large systemic savings without jeopardizing future innovation.
53,665 views  |  
Oct 22, 2019

Medicare’s Denial Of Coverage To Kidney Patients Could Be Just The Beginning

CMS is unjustifiably denying kidney patients an effective medicine for anemia, which commonly afflicts patients with kidney disease. This denial will lead to higher cost, lower-quality care for kidney patients today. It also foreshadows the potential future under "Medicare for All".
793 views  |  
Oct 18, 2019

Price Controls Are Not The Answer To Expensive Drugs

Policymakers continue to propose price controls as a means to reduce the high cost of drugs. Speaker Pelosi's plan (H.R. 3) is the latest example. History shows that price controls always hurt the people they are supposed to help, and imposing price controls on drugs will be no different.
More Articles
November 2019 (1)
Nov 7, 2019
There Are High Costs From Implementing Drug Price Controls
October 2019 (4)
September 2019 (1)
August 2019 (4)
July 2019 (2)
June 2019 (1)
May 2019 (3)
April 2019 (5)
March 2019 (1)
February 2019 (3)
January 2019 (1)
December 2018 (2)
November 2018 (3)
October 2018 (2)
September 2018 (3)
August 2018 (2)
July 2018 (1)
June 2018 (3)
March 2017 (1)
November 2016 (1)
October 2016 (1)
September 2015 (1)
August 2015 (1)
May 2015 (1)
March 2015 (1)
January 2015 (2)
December 2014 (1)
November 2014 (3)
July 2014 (2)
March 2014 (2)
December 2013 (1)
November 2012 (1)